Biocon Limited Stock

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Delayed NSE India S.E. 04:57:11 2024-06-10 am EDT 5-day change 1st Jan Change
341.3 INR +1.58% Intraday chart for Biocon Limited +10.19% +36.67%
Sales 2024 148B 1.77B Sales 2025 * 161B 1.93B Capitalization 401B 4.8B
Net income 2024 10.22B 122M Net income 2025 * 8.97B 107M EV / Sales 2024 2.14 x
Net Debt 2024 * 139B 1.67B Net Debt 2025 * 131B 1.57B EV / Sales 2025 * 3.29 x
P/E ratio 2024
30.9 x
P/E ratio 2025 *
45.9 x
Employees 16,545
Yield 2024 *
0.43%
Yield 2025 *
0.29%
Free-Float 37.18%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.00%
1 week+9.59%
Current month+9.73%
1 month+11.63%
3 months+21.54%
6 months+41.37%
Current year+35.93%
More quotes
1 week
269.55
Extreme 269.55
345.25
1 month
269.55
Extreme 269.55
345.25
Current year
244.55
Extreme 244.55
345.25
1 year
217.50
Extreme 217.5
345.25
3 years
191.55
Extreme 191.55
420.25
5 years
191.55
Extreme 191.55
487.75
10 years
65.88
Extreme 65.8833
487.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 13-04-30
Chief Executive Officer 65 22-12-11
Chairman 71 78-11-28
Members of the board TitleAgeSince
Chairman 71 78-11-28
Director/Board Member 69 99-12-31
Director/Board Member 60 18-07-26
More insiders
Date Price Change Volume
24-06-10 341.3 +1.58% 6 257 857
24-06-07 336 +0.98% 14,591,280
24-06-06 332.8 +9.01% 17,874,580
24-06-05 305.2 +4.93% 8,516,880
24-06-04 290.9 -6.06% 17,873,000

Delayed Quote NSE India S.E., June 10, 2024 at 02:19 am EDT

More quotes
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
336 INR
Average target price
296.6 INR
Spread / Average Target
-11.73%
Consensus
  1. Stock Market
  2. Equities
  3. BIOCON Stock